Anlon Healthcare Ltd

Anlon Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Anlon Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in its daily price, the stock’s technical indicators present a nuanced picture, reflecting both resilience and caution amid broader market fluctuations.

Anlon Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underpinned by a confluence of technical indicators including MACD, moving averages, and KST, suggesting a strengthening price momentum despite a slight dip in the latest trading session.

Anlon Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 June 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Anlon Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 June 2026, providing investors with the most up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Anlon Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 02 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Anlon Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently seen its quality grade upgraded from 'Does Not Qualify' to 'Average' as of 1 June 2026. This shift reflects notable changes in the company’s business fundamentals, including profitability metrics, debt levels, and operational consistency. This article delves into the specifics of these improvements and areas where challenges remain, providing investors with a comprehensive view of Anlon Healthcare’s evolving financial health.

Anlon Healthcare Ltd. delivered a robust profit recovery in Q4 FY26, posting consolidated net profit of ₹10.50 crores, marking a dramatic 103.88% sequential surge from the preceding quarter's ₹5.15 crores. The micro-cap pharmaceutical company, with a market capitalisation of ₹731.00 crores, demonstrated strong topline momentum as net sales climbed 43.03% quarter-on-quarter to ₹50.89 crores, though operating margins contracted to 30.05% from 34.49% in Q3 FY26. The stock closed at ₹13.59 on June 1, 2026, down 2.79% from the previous session, reflecting cautious investor sentiment despite the headline profit growth.